Validación del cuestionario de satisfacción con el tratamiento antirretroviral: cuestionario CESTA
Emilia Condés(Hospital Universitario de Móstoles), Daniel Podzamczer(Bellvitge University Hospital), Luís Force(Hospital de Poniente), José Manuel Márquez Estrada(Hospital Clínico San Carlos), David Dalmau(University Hospital Mútua de Terrassa), Xavier Badía(Oblikue Consulting (Spain)), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Koldo Aguirrebengoa(Hospital de Cruces)
Cited by 11
Related Papers
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
A Randomized, Double‐Blind, Double‐Dummy, Multicenter Trial of Voriconazole and Fluconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients
|Clinical Infectious Diseases|2001|334
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
|Proceedings of the National Academy of Sciences|2022|198
Severe Dengue Virus Infection in Travelers: Risk Factors and Laboratory Indicators
|The Journal of Infectious Diseases|2007|173